- Home
- FFIE vs CRDL Comparison
FFIE vs CRDL Comparison
Compare FFIE & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFIE
- CRDL
- Stock Information
- Founded
- FFIE 2014
- CRDL 2017
- Country
- FFIE United States
- CRDL Canada
- Employees
- FFIE N/A
- CRDL N/A
- Industry
- FFIE Auto Manufacturing
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FFIE Consumer Discretionary
- CRDL Health Care
- Exchange
- FFIE Nasdaq
- CRDL Nasdaq
- Market Cap
- FFIE 97.5M
- CRDL 102.0M
- IPO Year
- FFIE N/A
- CRDL N/A
- Fundamental
- Price
- FFIE $1.60
- CRDL $1.20
- Analyst Decision
- FFIE
- CRDL Strong Buy
- Analyst Count
- FFIE 0
- CRDL 3
- Target Price
- FFIE N/A
- CRDL $9.00
- AVG Volume (30 Days)
- FFIE 11.5M
- CRDL 274.8K
- Earning Date
- FFIE 11-06-2024
- CRDL 03-31-2025
- Dividend Yield
- FFIE N/A
- CRDL N/A
- EPS Growth
- FFIE N/A
- CRDL N/A
- EPS
- FFIE N/A
- CRDL N/A
- Revenue
- FFIE $537,000.00
- CRDL N/A
- Revenue This Year
- FFIE $10,958.67
- CRDL N/A
- Revenue Next Year
- FFIE $617.65
- CRDL N/A
- P/E Ratio
- FFIE N/A
- CRDL N/A
- Revenue Growth
- FFIE N/A
- CRDL N/A
- 52 Week Low
- FFIE $0.99
- CRDL $1.15
- 52 Week High
- FFIE $156.00
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- FFIE 51.72
- CRDL 41.60
- Support Level
- FFIE $1.49
- CRDL $1.15
- Resistance Level
- FFIE $1.86
- CRDL $1.51
- Average True Range (ATR)
- FFIE 0.18
- CRDL 0.10
- MACD
- FFIE 0.04
- CRDL -0.01
- Stochastic Oscillator
- FFIE 46.84
- CRDL 13.65
About FFIE Faraday Future Intelligent Electric Inc.
Faraday Future Intelligent Electric Inc is a global shared intelligent mobility ecosystem. It is poised to break the boundaries between the Internet, IT, creative, and auto industries with product and service offerings that integrate new energy, AI, Internet, and sharing models.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.